Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-09-10-Speech-1-249-000"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| lpv:document identification number |
"en.20120910.29.1-249-000"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:translated text |
"Madam President, the Commission is grateful for Parliament’s support for the first reading agreement on the pharmacovigilance proposals.
With regard to the black box referred to by Ms McAvan, there is an ongoing project to analyse the feasibility and value added of certain information that will be summarised in what is now being called the drug fact box. The studies will involve collaboration with the European Medicines Agency and national competent authorities, as well as consultations with organisations at EU level representing patients, consumers, doctors and pharmacists, social health insurers and industry. The report on the readability of the package information requested by Parliament in 2010 and the outcome of the study on the drug fact box is expected to be ready by mid-2013.
I agree with Ms Matias that we cannot allow the financial crisis to punch holes in our health care system. Health is, in my view, a fundamental right of all our citizens. Apart from this, health is a major motor of economic growth, and cutting health is based on a major fallacy. We look forward to the adoption of the new legislation and its application, which will benefit EU citizens by strengthening both safety and transparency, and, in particular, to a greater number of medicinal products that will be subject to increased monitoring."@en1
|
| lpv:unclassifiedMetadata | |
| lpv:videoURI |
Named graphs describing this resource:
The resource appears as object in 2 triples